Reimagining RNA medicine

Aug 12, 2024

Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy

Aug 08, 2024

Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 01, 2024

Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

Jun 25, 2024

Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease

Jun 12, 2024

Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing

May 30, 2024

Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference

May 09, 2024

Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 09, 2024

Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

May 07, 2024

Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference

May 02, 2024

Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024